A Phase 2/3 Efficacy and Safety Study of PF-07321332/Ritonavir in Nonhospitalized Low-Risk Adult Participants With COVID-19. (Covid 1002)


To compare the efficacy of PF-07321332/ritonavir to placebo for the treatment of symptomatic COVID-19 in nonhospitalized adult participants with COVID-19 who are at low risk of progression to severe disease. (Pfizer 1002)


1. At least 18 years old.

2. Confirmed SARS-COV -2 infection within 5 days prior to start of study.

3. Experiencing at least one symptom of Covid-19. (Cough, shortness of breath, fever, fatigue, chills, muscle aches, diarrhea, nausea, headache, sore throat, congestion, loss of taste or smell.)

You cannot:

1.  Have an underlying condition that would cause you to be at greater risk of developing severe Covid-19 symptoms. (Obesity, 60 years old or older, current smoker, chronic lung disease, diabetes, kidney disease, heart disease, sickle cell, active cancer) **IF FULLY VACCINATED FOR COVID-19 ABOVE RISK FACTORS ACCEPTABLE**

2.  Have an immunosuppressive disease.

3.  Have ever been hospitalized for Covid-19.

4.  Have a past Covid-19 infection.

5.  Have received monoclonal antibodies for Covid-19


1.  Nasopharyngeal swabs and blood draws collected at select visits.

2.  Patient stipend.

3.  No cost of drug to patient.

4. Free Covid testing.

Interested in more information on clinical research? Contact WK Health System Clinical Research Department 318-212-8130 or ckay@wkhs.com

Interested in more information? Contact Us:

Joseph Bocchini, M.D., Principal Investigator

IRB: Advarra Institutional Review Board
IRB Number:
Trial Type: NA
Sponsor: Pfizer